MedTrace Logo

FAST Fish Phase IIb Clinical Trial for the Treatment of Fish Allergy by Subcutaneous Immunotherapy

NCT02382718 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-06-12

No results posted yet for this study

Summary

This is a phase IIb clinical trial to investigate the efficacy and safety of subcutaneous immunotherapy with a modified parvalbumin called mCyp c 1 for the treatment of fish allergy to subjects allergic to fish.

Conditions

  • Food Allergy to Fish

Interventions

BIOLOGICAL

FAST fish mCyp c 1

Subcutaneous immunotherapy

BIOLOGICAL

Placebo

Subcutaneous immunotherapy

Sponsors & Collaborators

  • Hospital San Carlos, Madrid

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • Medical University of Lodz

    collaborator OTHER

  • National and Kapodistrian University of Athens

    collaborator OTHER

  • Landspitali University Hospital

    collaborator OTHER

  • National University Hospital NUHD Denmark

    collaborator UNKNOWN

  • UMC Utrecht

    collaborator OTHER

  • Hospital Universitario Reina Sofia (Cordoba) Spain

    collaborator UNKNOWN

  • Hospital Regional de Malaga

    collaborator OTHER

  • George Stavroulakis

    lead OTHER

Principal Investigators

  • Ronald van Ree, Professor · FAST Consortium under EU 7th FP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-02-28
Completion
2017-04-30

Countries

  • Denmark
  • Greece
  • Iceland
  • Netherlands
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02382718 on ClinicalTrials.gov